ClinicalTrials.gg
RecruitingNCT06934421ReTaKRAUpdated Apr 24, 2025

Revised Targets for Knee Radiofrequency Ablation

An observational study in Osteoarthritis Knee Pain, sponsored by Centro Hospitalar Universitario do Algarve. Recruiting at 2 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Centro Hospitalar Universitario do Algarve · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Chronic Pain with a site in Portugal — 6 open to participants now, 6 under way, none of them phase 3. Chronic Pain · Portugal.

Started
2025
with 3 others
Observational
4 of 19
2 open now
Registered
13th of 19
by date
Lead sponsor
1 of 19
Centro Hospitalar Universitario do Algarve

Among the 19 studies in Chronic Pain with a site in Portugal, this one is one of 4 that started in 2025, is one of 4 observational ones, and was the 13th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

6 of the 19 studies in Chronic Pain with a site in Portugal are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Chronic Pain with a site in Portugal, or all of them as a file.
02

Study summary

This research team is doing a study to learn more about a new way to treat long-term knee pain caused by joint damage. They are using a treatment called radiofrequency ablation (RFA). This is a procedure where doctors use heat to stop certain nerves from sending pain signals.

In this study, doctors will use ultrasound to guide a small needle to nerves around the knee, called genicular nerves. Then, they will apply heat to those nerves using radiofrequency energy to help reduce pain.

The team created this new method based on recent studies of knee anatomy. They want to find out if this method can safely reduce pain and help people with knee joint damage move better. The study includes people who have moderate to severe knee damage and still have pain after trying medicine, physical therapy, or joint injections.

Each person in the study will have the treatment once. The research team will follow each person for two years. During this time, people in the study will answer simple questions about their knee pain and how it affects their daily life. The researchers will collect this information before the treatment and several times after it. One week after the procedure, the team will call each person to ask how they are feeling and check for any side effects.

Possible benefits of the study include less knee pain and easier movement. Possible risks include pain during the procedure, bruising, swelling, or short-term worsening of pain. Rare risks include nerve problems, weakness, bone damage, or allergic reaction.

The study is free for participants, and there is no payment. Taking part is voluntary. Anyone can stop being in the study at any time without affecting their medical care. The research team will keep all personal information private and secure.

Read the detailed description

This study applies a modified ultrasound-guided radiofrequency ablation (RFA) protocol for targeting the genicular nerves, informed by recent anatomical research. Conventional genicular nerve RFA techniques commonly rely on fluoroscopic or ultrasound guidance based on standard anatomical landmarks. However, cadaveric studies-such as those by Fonkoue et al. (2021)-have shown that these conventional approaches frequently miss the intended nerves, particularly the superomedial and superolateral branches, leading to inconsistent or suboptimal outcomes.

To address these limitations, this protocol incorporates revised probe positioning and alternative bony landmarks aligned with verified nerve pathways. The updated targeting strategy is designed to improve the precision and reproducibility of genicular nerve localization using high-resolution musculoskeletal ultrasound.

The procedure begins with ultrasound identification of the target genicular nerves. Once confirmed, a local anesthetic (2% lidocaine, 20-40 mg per site) is infiltrated to minimize discomfort. Thermal lesioning is then performed using standard 20G RF cannulas at 85°C for 90 seconds. Sensory stimulation (0.2-0.5 V) is used to verify appropriate referral patterns, and motor stimulation (2.0 V) is applied to rule out motor involvement before lesioning. If motor responses are elicited, repositioning or procedure cancellation is considered.

This anatomically informed technique aims to enhance procedural accuracy and consistency. By integrating cadaver-based nerve mapping with real-time ultrasound imaging, the approach has the potential to improve treatment effectiveness while maintaining a strong safety profile. The study will contribute clinical data supporting the feasibility and utility of this refined targeting method in managing knee pain related to joint degeneration.

03

Conditions studied

  • Osteoarthritis Knee Pain

Keywords

  • Genicular nerve
  • Knee pain
  • Chronic pain
  • Knee osteoarthritis
  • Radiofrequency ablation
  • Ultrasound guidance
  • Interventional pain management
  • Joint degeneration
  • Nerve ablation
  • Image-guided procedures
  • Non-surgical treatment
  • Musculoskeletal intervention
  • Pain reduction
  • Functional improvement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from the community referred to the Physical and Rehabilitation Medicine department.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with chronic knee pain related to radiographic knee osteoarthritis, Kellgren-Lawrence (KL) grade III or IV, who are to conservative treatment.

(Refractoriness to conservative treatment is defined as:

  • Persistent pain and functional limitation after undergoing knee-targeted physiotherapy and analgesic medication in accordance with clinical guidelines for osteoarthritis [e.g., paracetamol, nonsteroidal anti-inflammatory drugs, and other drugs as deemed appropriate by the treating physician];
  • Persistent pain and functional limitation after intra-articular injections or limited success with such interventions.)

Exclusion criteria

Exclusion Criteria:

  • Patients with previous knee arthroplasty
  • Patients who have undergone prior radiofrequency (RF) ablation
  • Significant psycho-emotional disorders
  • Addictive behaviors
  • Generalized pain
  • Nociplastic pain
  • Presence of a pacemaker
  • Presence of osteosynthesis material in the knee or adjacent anatomical regions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single-Session Ultrasound-Guided Genicular Nerve Radiofrequency Ablation in Patients With Knee Osteo

    Participants with knee osteoarthrosis (Kellgran-Lawrence III or IV) will receive a single-session ultrasound-guided radiofrequency ablation of the genicular nerves. The procedure targets three specific nerve branches around the knee joint: the superomedial, superolateral, and inferomedial genicular nerves. The targeted positions are based on anatomical reference points described by Fonkoue et al. (2021) and validated in cadaveric studies, aiming to improve the accuracy of nerve localization. Under ultrasound guidance, the clinician will insert a radiofrequency needle at each target site. After confirming correct positioning through sensory and motor stimulation, thermal ablation will be performed at 85ºC for 90 seconds per site. Local anesthesia will be administered before each ablation to ensure patient comfort. This procedure aims to reduce knee pain and improve function in patients with moderate to severe knee joint degeneration who have not responded to conservative treatments.

    Device: Ultrasound-Guided Genicular Nerve Radiofrequency Ablation

Interventions

  • DeviceUltrasound-Guided Genicular Nerve Radiofrequency Ablation

    This intervention involves a single-session ultrasound-guided thermal radiofrequency ablation of the superomedial, superolateral, and inferomedial genicular nerves in patients with moderate to severe knee osteoarthritis. Target points follow anatomical references described by Fonkoue et al. and validated in cadaveric studies, differing from classical approaches. Under ultrasound guidance, monopolar RF cannulas are placed, with sensory and motor stimulation confirming accurate positioning. Local anesthesia (2% lidocaine) is applied. Lesions are performed at 85°C for 90 seconds per site. The radiofrequency generator used is CE-marked for pain procedures. The study evaluates a novel targeting protocol, not the safety or effectiveness of the device itself. No fluoroscopy is used. The procedure is performed once. Participants are followed for two years to assess outcomes.

    Also known as: Thermal Radiofrequency Ablation of Genicular Nerves, Monopolar Radiofrequency Ablation of Knee Nerves, Image-Guided Genicular Nerve Ablation, Ultrasound-Guided RFA of Knee, Genicular Nerve RFA, RFA for Knee Osteoarthritis Pain

06

What researchers measure

Primary outcomes

  1. Change in Knee Pain Intensity (Numeric Pain Rating Scale - NPRS)

    Change in patient-reported knee pain at rest and during movement, measured using an 11-point Numeric Pain Rating Scale (0 = no pain, 10 = worst imaginable pain).

    Time frame: Baseline to 3 months post-procedure

Secondary outcomes

  1. Change in Physical Function (WOMAC Functional Subscale)

    Change in physical function as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Physical Function Subscale. The WOMAC is a validated, self-reported questionnaire assessing functional limitations due to knee osteoarthritis. This subscale includes 17 items, each scored on a Likert scale from 0 to 4. The total score ranges from 0 to 68, with higher scores indicating worse physical function.

    Time frame: Baseline to 3 months, 6 months, 1 year, and 2 years post-procedure

  2. Sustained Pain Reduction (Numeric Pain Rating Scale)

    Change in pain intensity over time as measured by the Numeric Pain Rating Scale (NPRS). The NPRS is an 11-point scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "worst imaginable pain". Patients will report their average knee pain intensity over the past 24 hours. Higher scores indicate worse pain. This outcome assesses the duration and consistency of the analgesic effect following the radiofrequency ablation procedure.

    Time frame: Baseline to 1 week, 1 month, 3 months, 6 months, 1 year, and 2 years post-procedure

  3. Incidence of Adverse Events

    Number and type of adverse events related to the intervention, including local site pain, edema, bruising, motor weakness, neuritis, or other complications.

    Time frame: From procedure day to 2-year follow-up

  4. Responder Rate (≥50% Pain Reduction)

    Proportion of participants achieving ≥50% reduction in NPRS at 3 months post-procedure compared to baseline.

    Time frame: Baseline to 3 months post-procedure

07

Study locations

1 of 2 sites recruiting
  • Serviço de Medicina Física e de Reabilitação - Hospital de Faro - Unidade Local de Saúde do Algarve
    Faro, 8000-386, Portugal
    Recruiting
    • Manuel Tomás Farinha Caroço, Medical Doctor · Contactfarinhacaroco@gmail.com · 968010683
    • Daniela Teixeira, Medical Doctor · Contactdanielaspteixeira@gmail.com · +351 914 511 022
    • Manuel Tomás Farinha Caroço, Medical Doctor · Principal investigator
  • Serviço de Medicina Física e de Reabilitação - Hospital de São Francisco Xavier - Unidade Local de Saúde de Lisboa Ocidental
    Lisboa, 1449-005, Portugal
    Not yet recruiting
    • Giovanni Leoni, Medical Doctor · Contactgioleoni95@gmail.com · +39 328 613 3631
    • Jorge Barbosa, Medical Doctor · Contactjbarbosa@chlo.min-saude.pt · +351 914 729 415
    • Giovanni Leoni, Medical Doctor · Principal investigator
08

References and documents

Publications

  • Cohen SP, Bhaskar A, Bhatia A, Buvanendran A, Deer T, Garg S, Hooten WM, Hurley RW, Kennedy DJ, McLean BC, Moon JY, Narouze S, Pangarkar S, Provenzano DA, Rauck R, Sitzman BT, Smuck M, van Zundert J, Vorenkamp K, Wallace MS, Zhao Z. Consensus practice guidelines on interventions for lumbar facet joint pain from a multispecialty, international working group. Reg Anesth Pain Med. 2020 Jun;45(6):424-467. doi: 10.1136/rapm-2019-101243. Epub 2020 Apr 3. PubMed 32245841 ↗
  • Pardal, Margarida Alexandra Rodrigues. Adaptação cultural para português europeu do Western Ontario and McMaster Universities Arthritis Index (WOMAC). Master's Thesis 2023;
  • De Cassai A, Dost B, Tulgar S. Enhancing the clarity and reproducibility of regional anesthesia techniques: a call for video integration in scientific publications. Reg Anesth Pain Med. 2024 Jul 23:rapm-2024-105871. doi: 10.1136/rapm-2024-105871. Online ahead of print. No abstract available. PubMed 39043621 ↗
  • Tran J, Peng P, Agur A. Evaluation of nerve capture using classical landmarks for genicular nerve radiofrequency ablation: 3D cadaveric study. Reg Anesth Pain Med. 2020 Nov;45(11):898-906. doi: 10.1136/rapm-2020-101894. Epub 2020 Sep 14. PubMed 32928998 ↗
  • Tran J, Peng PWH, Chan VWS, Agur AMR. Overview of Innervation of Knee Joint. Phys Med Rehabil Clin N Am. 2021 Nov;32(4):767-778. doi: 10.1016/j.pmr.2021.05.011. Epub 2021 Jul 14. PubMed 34593142 ↗
  • Fonkoue L, Stoenoiu MS, Behets CW, Steyaert A, Kouassi JK, Detrembleur C, Cornu O. Validation of a new protocol for ultrasound-guided genicular nerve radiofrequency ablation with accurate anatomical targets: cadaveric study. Reg Anesth Pain Med. 2021 Mar;46(3):210-216. doi: 10.1136/rapm-2020-101936. Epub 2020 Dec 3. PubMed 33273065 ↗
  • Fonkoue L, Behets C, Kouassi JK, Coyette M, Detrembleur C, Thienpont E, Cornu O. Distribution of sensory nerves supplying the knee joint capsule and implications for genicular blockade and radiofrequency ablation: an anatomical study. Surg Radiol Anat. 2019 Dec;41(12):1461-1471. doi: 10.1007/s00276-019-02291-y. Epub 2019 Jul 23. PubMed 31338537 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in publications will be shared. This includes pain scores, functional outcomes (WOMAC), adverse event data, and baseline clinical and demographic variables such as age, sex, body mass index (BMI), radiographic knee imaging (image and Kellgren-Lawrence grade), painful knee quadrant, presence of depressive symptoms, and use of opioids, antidepressants, or anxiolytics. A data dictionary will be provided to support interpretation of the dataset.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Individual participant data (IPD) and supporting information will be available beginning 6 months after publication of the primary results. Data will remain available for a period of 5 years.

Access criteria: Researchers who wish to access individual participant data (IPD) must submit a written request including a clear research question, rationale, and a detailed statistical analysis plan. The proposed analyses must be scientifically sound, ethically appropriate, and feasible given the dataset. Proposals must demonstrate consistency with the objectives of academic, non-commercial research. All requests will be reviewed by the principal investigator and the study's coordinating research team to ensure alignment with ethical standards and scientific merit. If the request is approved, the researcher will be required to sign a data sharing agreement that outlines the terms of use, including data confidentiality, appropriate use, and prohibition of re-identification. Approved data will be shared in de-identified format through a secure institutional repository or via encrypted file transfer. Requests and supporting documents can be submitted by email to the principal investigator.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Jul 2028, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 18, 2025
StartActual
Mar 20, 2025
Primary completionEst.
Jul 14, 2028
CompletionEst.
Jul 30, 2031
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06934421
Lead sponsor
Centro Hospitalar Universitario do Algarve
Responsible party
Manuel Tomás Farinha Caroço (Medical Doctor, Centro Hospitalar Universitario do Algarve) — Principal investigator
First posted
Apr 18, 2025
Start date
Mar 20, 2025
Primary completion
Jul 14, 2028 (estimated)
Completion
Jul 30, 2031 (estimated)
Last update
Apr 24, 2025

Study contacts

Manuel Tomás Farinha Caroço, Medical Doctor
Contact
farinhacaroco@gmail.com
+351968010683
Giovanni Leoni, Medical Doctor
Contact
gioleoni95@gmail.com
+39 328 613 3631
Manuel Tomás Farinha Caroço, Medical Doctor
principal investigator · Unidade Local de Saude do Algarve / Centro Hospitalar Universitario Algarve

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion